Post-Marketing Study to Assess the Safety & Efficacy of RenalGuard® Therapy for Prevention CSA-AKI
Not Applicable
Recruiting
- Conditions
- AKI - Acute Kidney InjuryCardiac Surgery Associated - Acute Kidney Injury
- First Posted Date
- 2025-02-06
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- CardioRenal Systems, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06811805
- Locations
- 🇧🇪
Jessa Medica Center, Hasselt, Belgium
🇩🇪TUM Klinikum Deutsches Herzzentrum, Munich, Germany
🇩🇪Uniklinikum Munster, Munster, Germany
TARGET: A Study to Evaluate the Treatment of Patients With Acute Decompensated Heart Failure (ADHF) Using an Automated Fluid Management System
Not Applicable
- Conditions
- Congestive Heart Failure
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- CardioRenal Systems, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03897842
- Locations
- 🇵🇱
Military Hospital of Wroclaw, Wroclaw, Poland
Reprieve ADHF EFS IDE
Not Applicable
- Conditions
- Congestive Heart Failure
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2019-03-07
- Lead Sponsor
- CardioRenal Systems, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03866551
Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients
Phase 3
Active, not recruiting
- Conditions
- Contrast Induced Nephropathy
- Interventions
- Device: RenalGuard TherapyDrug: Standard Therapy
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- CardioRenal Systems, Inc.
- Target Recruit Count
- 326
- Registration Number
- NCT01456013
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸Torrance Medical Center, Torrance, California, United States
🇺🇸Washington Hospital Center, Washington, District of Columbia, United States